Latest Biotech News

SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings, signaling continued investor appetite for clinical-stage biotechs following the J.P. Morgan conference. Both companies...

Advocates urged House representatives to back a FY2026 budget that preserves the Senate Appropriations Committee’s NIH funding level of $48.7 billion and maintains Senate language protecting...

AbbVie and Genmab disclosed that Epkinly (loncastuximab tesirine) did not extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The companies reported topline...

Sarepta Therapeutics reported preliminary Q4 product revenue that missed analyst expectations for its AAV gene therapy Elevidys, with Q4 Elevidys revenue down 17% from the prior quarter. CEO...

ImmunityBio reported early trial data showing its off‑the‑shelf allogeneic CD19 CAR‑NK therapy, given with rituximab, produced durable complete responses in Waldenström’s macroglobulinemia...

The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s footprint across Europe, aiming to accelerate translational startups and commercialization of...

SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings, aiming to capitalize on investor interest generated during JPM week and recent biotech market momentum. Both companies...

BioCentury reported innovators are converting extracellular targeted protein degraders (TACs) into bispecific formats that exploit membrane E3 ligases and novel lysosomal internalizing receptors....

The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema who failed topical corticosteroids or cannot use them. Regulators emphasized the topical...

An NTU Singapore–University of Geneva team published in Science Advances that Enterococcus faecalis uses extracellular electron transport (EET) to generate reactive oxygen species, activate the...

Researchers at Memorial Sloan Kettering showed in Nature Cancer that disseminated lung adenocarcinoma cells can undergo a TGFβ‑driven atypical epithelial‑to‑mesenchymal transition (EMT) that ends...

A study in the Journal of Translational Medicine reported that fratricide‑driven, unedited CD7 CAR‑T cells produced anti‑leukemic activity in preclinical models of T‑cell leukemia. The approach...

ImmunityBio reported durable complete responses in early data from an allogeneic, off‑the‑shelf CD19 CAR‑NK program combined with rituximab in patients with Waldenström’s non‑Hodgkin lymphoma. The...

AbbVie and Genmab disclosed that Epkinly (their anti‑CD47/PD‑1 program or other named asset in a late‑stage study) did not prolong overall survival in a Phase 3 trial for diffuse large B‑cell...

UC San Diego secured an ARPA‑H award of up to $25,771,771 over 60 months to develop patient‑specific, 3D‑bioprinted human livers intended as an alternative to donor transplantation. The...

The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema (CHE) who have inadequate response to topical corticosteroids or cannot use them....

Columbia University spinout Foli Bio is developing stool‑based RNA‑seq panels that use exfoliated fecal RNA to predict drug response and monitor inflammatory bowel disease (IBD), with the stated...

Spanish diagnostics firm Destina Genomica received €2.2 million from the European Innovation Council (EIC) to accelerate clinical transition of its LiverAce Combo assay for drug‑induced liver...

Reporting shows internal unease at the FDA about a new expedited drug program after staff described instances where usual review steps were bypassed and senior leaders were reluctant to sign off...

The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s reach from Denmark to startups across Europe. The funding aims to expand early‑stage support,...